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Introduction {#ehf212407-sec-0004}
============

The 2013 American College of Cardiology/American Heart Association Guidelines for the Management of Heart Failure (HF) and the 2016 European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and Chronic HF recommend implantable cardioverter‐defibrillator (ICD) implantation for prevention of death in patients with HF with reduced ejection fraction.[1](#ehf212407-bib-0001){ref-type="ref"}, [2](#ehf212407-bib-0002){ref-type="ref"} While there is considerable evidence that ICDs prevent death in patients with ischaemic cardiomyopathy (ICM),[3](#ehf212407-bib-0003){ref-type="ref"}, [4](#ehf212407-bib-0004){ref-type="ref"} the evidence for patients with non‐ischaemic cardiomyopathy (NICM) is less robust.

The Defibrillators in Non‐Ischaemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial[5](#ehf212407-bib-0005){ref-type="ref"} did not show a significant survival benefit for ICD, though there was a trend towards mortality reduction. Similarly, although the Sudden Cardiac Death in Heart Failure Trial (SCD‐HeFT) demonstrated improved mortality with ICD therapy for patients with cardiomyopathy, the subgroup analysis for non‐ischaemic patients showed attenuated benefit.[4](#ehf212407-bib-0004){ref-type="ref"} More recently, the Danish Study to Assess the Efficacy of ICDs in Patients with Non‐Ischaemic Systolic Heart Failure on Mortality (DANISH) trial[6](#ehf212407-bib-0006){ref-type="ref"} failed to show a survival benefit for ICDs compared with optimal medical therapy. However, updated meta‐analyses[7](#ehf212407-bib-0007){ref-type="ref"}, [8](#ehf212407-bib-0008){ref-type="ref"}, [9](#ehf212407-bib-0009){ref-type="ref"}, [10](#ehf212407-bib-0010){ref-type="ref"}, [11](#ehf212407-bib-0011){ref-type="ref"} continue to suggest a survival benefit for ICD implantation among patients with NICM, a recommendation that is reflected in current guidelines. For these reasons, there is considerable interest in additional analyses of whether the impact of having an ICD may differ depending on HF aetiology.[12](#ehf212407-bib-0012){ref-type="ref"}

The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, a large randomized, clinical trial of patients with HF with reduced ejection fraction that tested the effect of warfarin vs. aspirin on death and stroke, provides an important opportunity to address this critical question. We conducted an analysis using WARCEF data to further elucidate the relation between ICD status and mortality for HF patients with ICM and NICM, using a propensity score‐based approach to limit confounding.

Methods {#ehf212407-sec-0005}
=======

Study participants {#ehf212407-sec-0006}
------------------

The investigation conforms with the principles outlined in the Declaration of Helsinki. Details of the WARCEF trial have been published previously.[13](#ehf212407-bib-0013){ref-type="ref"} A total of 2305 patients with left ventricular ejection fraction ≤ 35% in sinus rhythm were randomly assigned to warfarin (target international normalized ratio 2.75, with an acceptable target range of 2.0 to 3.5) or aspirin (325 mg/day). Left ventricular ejection fraction was measured by radionuclide ventriculography, left ventriculography, or quantitative echocardiography. Based on those findings and patients\' past medical history, the aetiology of HF was determined by clinical judgement of each local site. Patients were enrolled at 168 centres in 11 countries between October 2002 and January 2010. The mean follow‐up time was 3.5 ± 1.8 years. Patients who had a clear indication for warfarin or aspirin were not eligible. Additional eligibility criteria were a modified Rankin score of 4 or less (on a scale of 0 to 6, with higher scores indicating more severe disability) and planned treatment with a beta‐blocker, an angiotensin‐converting enzyme (ACE)‐Inhibitor \[or, if the side‐effect profile with ACE‐Inhibitors was unacceptable, with an angiotensin II receptor blocker (ARB)\], or hydralazine and nitrates. Patients were ineligible if they had a condition that conferred a high risk of cardiac embolism, such as atrial fibrillation, a mechanical cardiac valve, endocarditis, or an intracardiac mobile or pedunculated thrombus.

For this analysis, we excluded 12 enrolled patients because of lack of data on either aetiology of HF or ICD status at baseline (*Figure* [*1*](#ehf212407-fig-0001){ref-type="fig"}). Information regarding indications for ICD, and whether or not the patients received concurrent cardiac resynchronization therapy (CRT), was not recorded in WARCEF.

![Overview of the study cohort. ICD, implantable cardioverter‐defibrillator.](EHF2-6-297-g001){#ehf212407-fig-0001}

Assessment of outcomes {#ehf212407-sec-0007}
----------------------

In the WARCEF trial, an independent endpoint adjudication committee, whose members were unaware of the treatment assignment, adjudicated major clinical outcomes. The committee adjudicated cause of death based on the standardized narrative reports on patients\' status preceding death. If applicable and available, discharge summary; detailed report by physician, nursing staff, or family; autopsy report; death certificate; and other materials were considered as materials for adjudication. Post‐mortem ICD interrogation was not always available but was considered in adjudication process if it was available. In the current analysis, the primary outcome was all‐cause death, and the secondary outcomes were cardiovascular death and sudden death. Deaths were adjudicated as having a cardiovascular or non‐cardiovascular cause, and cardiovascular deaths were then adjudicated as sudden or other types. The adjudication was not blinded to ICD status.

Statistical analysis {#ehf212407-sec-0008}
--------------------

Baseline characteristics were assessed by ICD status and for ICM and NICM groups separately. Continuous variables are presented as mean ± SD and categorical variables as frequencies and percentages. They were considered balanced if the standardized bias was less than 0.25.[14](#ehf212407-bib-0014){ref-type="ref"} This is the difference in means (for continuous variables) or proportions (for each category of a categorical variable) divided by the pooled standard deviation.

A propensity score matching approach was used to adjust for potential confounding in the comparison of patients who had or did not have implanted ICDs at randomization.[15](#ehf212407-bib-0015){ref-type="ref"}, [16](#ehf212407-bib-0016){ref-type="ref"} The goal is to assess whether any ICD benefit differs between NICM and ICM patients, rather than to measure ICD benefit in the overall population. We therefore match ICD to non‐ICD patients within the NICM stratum and, separately, ICD to non‐ICD patients within the ICM stratum.The propensity score model initially included 41 patient covariates, NICM vs. ICM status, and the interaction of this status with each of the covariates in a logistic regression model. To avoid overfitting, the final model included the subset of predictor variables that optimized the Akaike information criterion in a stepwise procedure.

We implemented the matching procedure with the R package MatchIt.[17](#ehf212407-bib-0017){ref-type="ref"} We first selected matched controls using random selection within a calliper width of SD 0.1 on the logit scale. That is, for each case, we considered the set of controls whose logit propensity score was within 0.1 SDs of the logit propensity score of the case and randomly selected two from the set as the matched controls. If no matches were available within the calliper, we used the nearest neighbour control to match the case. In this way, we were able to match all cases to controls within each stratum.

To assess the association between ICD status and outcomes by aetiology of HF and to determine whether aetiology of HF modulated the association between ICD status and mortality, we constructed Cox proportional hazards models including ICD, ICM, and their interaction as covariates separately for all‐cause death, cardiovascular death, and sudden death. Time zero was defined as the time of randomization in the survival analyses. Robust variance estimators were used to adjust for any clustering caused by the matching. Two‐tailed *P* values \< 0.05 were considered statistically significant. All analyses were performed using SAS (version 9.4; SAS Institute, Cary, North Carolina) and R.

Results {#ehf212407-sec-0009}
=======

Baseline characteristics {#ehf212407-sec-0010}
------------------------

The flowchart for the analysis procedure is presented in *Figure* [*1*](#ehf212407-fig-0001){ref-type="fig"}. Of the 2293 WARCEF participants, 418 had an ICD at time of enrolment (ICM, *N* = 223; NICM, *N* = 195) (*Figure* [*1*](#ehf212407-fig-0001){ref-type="fig"}). Before matching, ICM patients with ICDs were more likely to be from high‐income countries (i.e. excluding Argentina and Ukraine); younger; have higher education, lower systolic blood pressure, alcohol consumption, ARB, lower sodium level; and less likely to have ACE‐Inhibitor, as compared with ICM patients without ICDs. NICM patients with ICDs were more likely to be from high‐income countries, have lower systolic blood pressure, and have a higher prevalence of past medical history of atrial fibrillation, have longer distance on 6 min walk test, and were more likely to take diuretics, as compared with NICM patients without ICDs (*Table* [1](#ehf212407-tbl-0001){ref-type="table"}). We matched 205 ICM cases to controls and 189 NICM cases to controls using the calliper criterion and 18 ICM cases to controls and 6 NICM cases to controls using the nearest neighbour procedure. The standardized biases of all baseline covariates were less than 0.25 after matching (*Table* [2](#ehf212407-tbl-0002){ref-type="table"}). Variables with high or moderate missingness include aldosterone blocker (32%), statin (21%), previous aspirin use (19%), 6 min walk (7%), and haemoglobin (6%). Missingness in other variables was negligible. Aldosterone blocker and 6 min walk entered the final propensity score model, with missing values imputed by mode and mean, respectively.

###### 

Patient characteristics before propensity score matching

  Characteristics                                  Ischaemic        Non‐ischaemic                                               
  ------------------------------------------------ ---------------- ---------------- ------- ---------------- ----------------- -------
  Treatment arm                                                                                                                 
  Warfarin                                         108/223 (48.4)   380/768 (49.5)    0.021  104/195 (53.3)   546/1107 (49.3)    0.08
  Demographics                                                                                                                  
  Middle‐income countries (Argentina or Ukraine)   3/223 (1.3)      98/768 (12.8)     0.377  3/195 (1.5)      103/1107 (9.3)     0.284
  Age, years                                       61.1 ± 10.0      63.8 ± 10.2       0.271  58.1 ± 12.2      59.1 ± 11.8        0.09
  Age categories                                                                                                                
  \<60                                             92/223 (41.3)    265/768 (34.5)    0.141  107/195 (54.9)   558/1107 (50.4)    0.089
  60--74                                           114/223 (51.1)   374/768 (48.7)    0.048  72/195 (36.9)    432/1107 (39.0)    0.043
  \>74                                             17/223 (7.6)     129/768 (16.8)    0.259  16/195 (8.2)     117/1107 (10.6)    0.078
  Male sex                                         199/223 (89.2)   655/768 (85.3)    0.114  154/195 (79.0)   829/1107 (74.9)    0.095
  Race or ethnic group                                                                                                          
  Non‐Hispanic White                               177/223 (79.4)   604/768 (78.6)    0.018  139/195 (71.3)   809/1107 (73.1)    0.04
  Non‐Hispanic Black                               26/223 (11.7)    65/768 (8.5)      0.111  41/195 (21.0)    198/1107 (17.9)    0.081
  Hispanic                                         13/223 (5.8)     72/768 (9.4)      0.127  9/195 (4.6)      72/1107 (6.5)      0.078
  Other                                            7/223 (3.1)      27/768 (3.5)      0.021  6/195 (3.1)      28/1107 (2.5)      0.034
  Educational level                                                                                                             
  \< High school                                   73/221 (33.0)    376/767 (49.0)    0.321  72/195 (36.9)    469/1106 (42.4)    0.111
  High school graduate or some college             109/221 (49.3)   284/767 (37.0)    0.251  95/195 (48.7)    455/1106 (41.1)    0.153
  College graduate or postgraduate                 39/221 (17.6)    107/767 (14.0)    0.104  28/195 (14.4)    182/1106 (16.5)    0.057
  Body measurement and vital statistics                                                                                         
  Height, cm                                       172.4 ± 8.9      171.5 ± 9.0       0.099  172.9 ± 9.5      171.4 ± 9.5        0.166
  Weight, kg                                       86.5 ± 16.5      84.6 ± 17.6       0.111  89.0 ± 21.5      86.5 ± 20.8        0.118
  Body mass index mean                             29.1 ± 5.2       28.7 ± 5.4        0.07   29.7 ± 7.2       29.3 ± 6.3         0.067
  Body mass index distribution                                                                                                  
  \<25                                             50/222 (22.5)    186/766 (24.3)    0.041  52/193 (26.9)    271/1098 (24.7)    0.052
  25--30                                           88/222 (39.6)    325/766 (42.4)    0.057  57/193 (29.5)    411/1098 (37.4)    0.164
  \>30                                             84/222 (37.8)    255/766 (33.3)    0.096  84/193 (43.5)    416/1098 (37.9)    0.116
  Systolic BP, mmHg                                119.1 ± 19.3     124.4 ± 17.6      0.29   119.9 ± 18.6     125.3 ± 19.4       0.278
  Pulse, beats/min                                 69.6 ± 10.1      71.2 ± 11.6       0.141  71.9 ± 11.3      73.0 ± 12.5        0.119
  Past medical history/co‐morbidities                                                                                           
  Hypertension                                     141/216 (65.3)   492/748 (65.8)    0.01   107/187 (57.2)   623/1076 (57.9)    0.014
  Diabetes mellitus                                92/223 (41.3)    283/768 (36.8)    0.091  50/195 (25.6)    297/1107 (26.8)    0.027
  Atrial fibrillation                              13/223 (5.8)     23/768 (3.0)      0.152  17/195 (8.7)     33/1107 (3.0)      0.299
  Peripheral vascular disease                      42/223 (18.8)    119/768 (15.5)    0.091  14/195 (7.2)     86/1107 (7.8)      0.022
  Prior stroke or TIA                              29/223 (13.0)    104/768 (13.5)    0.016  19/195 (9.7)     142/1106 (12.8)    0.094
  Alcohol and smoking                                                                                                           
  Smoking status                                                                                                                
  Current smoker                                   35/222 (15.8)    138/767 (18.0)    0.059  38/195 (19.5)    196/1106 (17.7)    0.046
  Former smoker                                    148/222 (66.7)   417/767 (54.4)    0.249  92/195 (47.2)    520/1106 (47.0)    0.003
  Never smoked                                     39/222 (17.6)    212/767 (27.6)    0.231  65/195 (33.3)    390/1106 (35.3)    0.04
  Alcohol consumption                                                                                                           
  Current consumption, \>2 oz/day                  65/223 (29.1)    179/768 (23.3)    0.136  48/195 (24.6)    279/1106 (25.2)    0.014
  Previous consumption, \>2 oz/day                 71/223 (31.8)    149/768 (19.4)    0.299  45/195 (23.1)    241/1106 (21.8)    0.031
  Never consumed alcohol                           87/223 (39.0)    440/768 (57.3)    0.366  102/195 (52.3)   586/1106 (53.0)    0.014
  Status of heart failure                                                                                                       
  NYHA classification                                                                                                           
  Class I                                          26/223 (11.7)    102/767 (13.3)    0.049  27/193 (14.0)    160/1102 (14.5)    0.015
  Class II                                         123/223 (55.2)   402/767 (52.4)    0.055  116/193 (60.1)   621/1102 (56.4)    0.076
  Class III                                        73/223 (32.7)    254/767 (33.1)    0.008  48/193 (24.9)    305/1102 (27.7)    0.063
  Class IV                                         1/223 (0.4)      9/767 (1.2)       0.073  2/193 (1.0)      16/1102 (1.5)      0.036
  Ejection fraction, %                             23.3 ± 6.8       25.0 ± 7.5        0.233  24.5 ± 7.3       24.7 ± 7.8         0.024
  LVEF ≤ 20%                                       76/223 (34.1)    195/768 (25.4)    0.195  55/194 (28.4)    324/1106 (29.3)    0.021
  Distance covered on 6 min walk, m                353.0 ± 126.6    341.4 ± 146.8     0.081  377.6 ± 124.4    352.8 ± 153.8      0.166
  Baseline MMSE score                              28.5 ± 2.0       28.4 ± 2.1        0.039  28.5 ± 2.0       28.6 ± 2.1         0.025
  Baseline MLWHF score                             37.5 ± 24.3      34.0 ± 22.5       0.153  32.9 ± 22.7      33.2 ± 24.4        0.011
  Medications                                                                                                                   
  Aspirin or other antiplatelet agents             136/190 (71.6)   446/599 (74.5)    0.065  104/141 (73.8)   572/781 (73.2)     0.012
  Warfarin or other oral anticoagulants            24/223 (10.8)    51/768 (6.6)      0.156  14/195 (7.2)     90/1107 (8.1)      0.035
  ACE‐Inhibitor                                    165/222 (74.3)   656/768 (85.4)    0.295  165/194 (85.1)   945/1105 (85.5)    0.013
  ARB                                              57/221 (25.8)    112/768 (14.6)    0.298  32/193 (16.6)    174/1104 (15.8)    0.022
  Beta‐blocker                                     209/223 (93.7)   682/768 (88.8)    0.163  181/194 (93.3)   986/1105 (89.2)    0.135
  Aldosterone blocker                              85/146 (58.2)    283/472 (60.0)    0.035  80/130 (61.5)    362/594 (60.9)     0.012
  Diuretic                                         185/223 (83.0)   614/768 (79.9)    0.076  168/194 (86.6)   884/1105 (80.0)    0.168
  Statin                                           185/196 (94.4)   541/611 (88.5)    0.194  118/150 (78.7)   546/717 (76.2)     0.059
  Lab data                                                                                                                      
  Creatinine, mg/dL                                1.2 ± 0.3        1.2 ± 0.3         0.184  1.2 ± 0.3        1.1 ± 0.3          0.113
  eGFR                                             64.5 ± 19.6      66.5 ± 19.9       0.099  69.2 ± 20.7      70.4 ± 21.0        0.054
  Haemoglobin, g/dL                                14.0 ± 1.8       14.1 ± 1.5        0.047  14.1 ± 1.5       14.1 ± 1.5         0.007
  Sodium, mEq/L                                    138.2 ± 9.5      139.8 ± 3.2       0.294  139.6 ± 3.4      139.8 ± 3.3        0.062
  WBC count, ×10^9^/L                              7.7 ± 2.0        7.5 ± 2.0         0.097  7.5 ± 2.4        7.4 ± 2.0          0.084

ACE‐Inhibitor, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; ICD, implantable cardio‐defibrillator; LVEF, left ventricular ejection fraction; MLWHF, Minnesota Living with Heart Failure questionnaire; MMSE, Mini‐Mental Scale Examination; NYHA, New York Heart Association; TIA, transient ischaemic attack; WBC, white blood cell.

###### 

Patient characteristics after propensity matching

  Variable                                         Ischaemic        Non‐ischaemic                                              
  ------------------------------------------------ ---------------- ---------------- ------- ---------------- ---------------- -------
  Treatment arm                                                                                                                
  Warfarin                                         108/223 (48.4)   223/446 (50.0)   0.031   104/195 (53.3)   184/390 (47.2)   0.123
  Demographics                                                                                                                 
  Middle‐income countries (Argentina or Ukraine)   3/223 (1.3)      9/446 (2.0)      0.051   3/195 (1.5)      6/390 (1.5)      0
  Age, years                                       61.1 ± 10.0      62.4 ± 9.6       0.135   58.1 ± 12.2      57.0 ± 11.7      0.091
  Age categories                                                                                                               
  \<60                                             92/223 (41.3)    171/446 (38.3)   0.06    107/195 (54.9)   228/390 (58.5)   0.073
  60--74                                           114/223 (51.1)   224/446 (50.2)   0.018   72/195 (36.9)    137/390 (35.1)   0.037
  \>74                                             17/223 (7.6)     51/446 (11.4)    0.126   16/195 (8.2)     25/390 (6.4)     0.07
  Male sex                                         199/223 (89.2)   395/446 (88.6)   0.021   154/195 (79.0)   302/390 (77.4)   0.037
  Race or ethnic group                                                                                                         
  Non‐Hispanic White                               177/223 (79.4)   358/446 (80.3)   0.022   139/195 (71.3)   277/390 (71.0)   0.006
  Non‐Hispanic Black                               26/223 (11.7)    49/446 (11.0)    0.021   41/195 (21.0)    88/390 (22.6)    0.037
  Hispanic                                         13/223 (5.8)     19/446 (4.3)     0.074   9/195 (4.6)      16/390 (4.1)     0.025
  Other                                            7/223 (3.1)      20/446 (4.5)     0.068   6/195 (3.1)      9/390 (2.3)      0.049
  Educational level                                                                                                            
  \< High school                                   73/221 (33.0)    186/445 (41.8)   0.18    72/195 (36.9)    134/390 (34.4)   0.054
  High school graduate or some college             109/221 (49.3)   196/445 (44.0)   0.106   95/195 (48.7)    191/390 (49.0)   0.005
  College graduate or postgraduate                 39/221 (17.6)    63/445 (14.2)    0.097   28/195 (14.4)    65/390 (16.7)    0.063
  Body measurement and vital statistics                                                                                        
  Height, cm                                       172.4 ± 8.9      172.2 ± 9.2      0.023   172.9 ± 9.5      172.9 ± 9.2      0.002
  Weight, kg                                       86.5 ± 16.5      86.1 ± 18.7      0.022   89.0 ± 21.5      89.5 ± 23.0      0.022
  Body mass index mean                             29.1 ± 5.2       29.0 ± 5.7       0.016   29.7 ± 7.2       29.7 ± 6.8       0
  Body mass index distribution                                                                                                 
  \<25                                             50/222 (22.5)    111/445 (24.9)   0.057   52/193 (26.9)    103/387 (26.6)   0.007
  25--30                                           88/222 (39.6)    176/445 (39.6)   0.002   57/193 (29.5)    120/387 (31.0)   0.032
  \>30                                             84/222 (37.8)    158/445 (35.5)   0.049   84/193 (43.5)    164/387 (42.4)   0.023
  Systolic BP, mmHg                                119.1 ± 19.3     120.9 ± 16.6     0.102   119.9 ± 18.6     121.7 ± 18.0     0.094
  Pulse, beats/min                                 69.6 ± 10.1      70.3 ± 11.3      0.064   71.5 ± 11.3      71.4 ± 12.2      0.005
  Co‐morbidities                                                                                                               
  Hypertension                                     141/216 (65.3)   274/427 (64.2)   0.023   107/187 (57.2)   217/374 (58.0)   0.016
  Diabetes mellitus                                92/223 (41.3)    178/446 (39.9)   0.027   50/195 (25.6)    96/390 (24.6)    0.024
  Atrial fibrillation                              13/223 (5.8)     20/446 (4.5)     0.062   17/195 (8.7)     24/390 (6.2)     0.1
  Peripheral vascular disease                      42/223 (18.8)    70/446 (15.7)    0.084   14/195 (7.2)     33/390 (8.5)     0.047
  Prior stroke or TIA                              29/223 (13.0)    69/446 (15.5)    0.07    19/195 (9.7)     43/389 (11.1)    0.043
  Alcohol and smoking                                                                                                          
  Smoking status                                                                                                               
  Current smoker                                   35/222 (15.8)    76/445 (17.1)    0.035   38/195 (19.5)    73/390 (18.7)    0.02
  Former smoker                                    148/222 (66.7)   281/445 (63.1)   0.073   92/195 (47.2)    177/390 (45.4)   0.036
  Never smoked                                     39/222 (17.6)    88/445 (19.8)    0.056   65/195 (33.3)    140/390 (35.9)   0.054
  Alcohol consumption                                                                                                          
  Current consumption, \>2 oz/day                  65/223 (29.1)    130/446 (29.1)   0       48/195 (24.6)    107/390 (27.4)   0.064
  Previous consumption, \>2 oz/day                 71/223 (31.8)    118/446 (26.5)   0.12    45/195 (23.1)    89/390 (22.8)    0.006
  Never consumed alcohol                           87/223 (39.0)    198/446 (44.4)   0.109   102/195 (52.3)   194/390 (49.7)   0.051
  Status of heart failure                                                                                                      
  NYHA classification                                                                                                          
  Class I                                          26/223 (11.7)    64/445 (14.4)    0.08    27/193 (14.0)    56/389 (14.4)    0.012
  Class II                                         123/223 (55.2)   229/445 (51.5)   0.074   116/193 (60.1)   235/389 (60.4)   0.006
  Class III                                        73/223 (32.7)    149/445 (33.5)   0.016   48/193 (24.9)    93/389 (23.9)    0.022
  Class IV                                         1/223 (0.4)      3/445 (0.7)      0.029   2/193 (1.0)      5/389 (1.3)      0.023
  LVEF, %                                          23.3 ± 6.8       24.2 ± 7.6       0.117   24.5 ± 7.3       24.3 ± 7.2       0.031
  LVEF ≤ 20%                                       76/223 (34.1)    139/446 (31.2)   0.062   55/194 (28.4)    111/390 (28.5)   0.002
  Distance covered on a 6 min walk, m              353.0 ± 126.6    359.3 ± 151.4    0.044   377.6 ± 124.4    377.7 ± 155.4    0.001
  Baseline MMSE score                              28.5 ± 2.0       28.4 ± 2.0       0.019   28.5 ± 2.0       28.6 ± 2.1       0.029
  Baseline MLWHF score                             37.5 ± 24.3      34.2 ± 22.7      0.144   32.9 ± 22.7      32.1 ± 24.7      0.033
  Medications                                                                                                                  
  Aspirin or other antiplatelet agents             136/190 (71.6)   248/344 (72.1)   0.011   104/141 (73.8)   196/273 (71.8)   0.044
  Warfarin or other oral anticoagulants            24/223 (10.8)    37/446 (8.3)     0.086   14/195 (7.2)     34/390 (8.7)     0.056
  ACE‐Inhibitor                                    165/222 (74.3)   354/446 (79.4)   0.121   165/194 (85.1)   319/390 (81.8)   0.086
  ARB                                              57/221 (25.8)    91/446 (20.4)    0.13    32/193 (16.6)    71/390 (18.2)    0.043
  Beta‐blocker                                     209/223 (93.7)   410/446 (91.9)   0.068   181/194 (93.3)   369/390 (94.6)   0.056
  Aldosterone blocker                              85/146 (58.2)    157/276 (56.9)   0.027   80/130 (61.5)    129/229 (56.3)   0.106
  Diuretic                                         185/223 (83.0)   370/446 (83.0)   0       168/194 (86.6)   339/390 (86.9)   0.01
  Statin                                           185/196 (94.4)   319/352 (90.6)   0.138   118/150 (78.7)   187/256 (73.0)   0.13
  Lab data                                                                                                                     
  Creatinine, mg/dL                                1.2 ± 0.3        1.2 ± 0.3        0.124   1.2 ± 0.3        1.2 ± 0.4        0.003
  eGFR                                             64.5 ± 19.6      66.4 ± 19.9      0.094   69.2 ± 20.7      69.7 ± 20.4      0.023
  Haemoglobin, g/dL                                14.0 ± 1.8       14.0 ± 1.6       0.024   14.1 ± 1.5       14.1 ± 1.5       0.041
  Sodium, mEq/L                                    138.2 ± 9.5      139.2 ± 3.2      0.161   139.6 ± 3.4      139.5 ± 3.3      0.014
  WBC count, ×10^9^/L                              7.7 ± 2.0        7.7 ± 2.1        0.033   7.5 ± 2.4        7.5 ± 2.2        0.019

ACE‐Inhibitor, angiotensin‐converting enzyme inhibitor; ARB, Angiotensin II receptor blocker; BP, blood pressure; eGFR, estimated glomerular filtration rate; ICD, implantable cardio‐defibrillator; LVEF, left ventricular ejection fraction; MLWHF, Minnesota Living with Heart Failure questionnaire; MMSE, Mini‐Mental Scale Examination; NYHA, New York Heart Association; TIA, transient ischaemic attack; WBC, white blood cell.

Values are mean ± SD or *n* (%).

Primary outcome: All‐cause death {#ehf212407-sec-0011}
--------------------------------

Kaplan--Meier curves for all‐cause death are presented in *Figure* [*2*](#ehf212407-fig-0002){ref-type="fig"}. Results from the Cox models are presented in *Table* [3](#ehf212407-tbl-0003){ref-type="table"}. There were 279 deaths in the current analysis (205 deaths among those without ICD and 74 deaths among those with ICD). For the 585 patients with NICM in the matched cohort, a total of 102 (17.4%) died during the follow‐up. These include 31 (15.9%) of the 195 patients with ICDs at baseline and 71 (18.2%) of the 390 matched patients who did not have ICDs. ICD status did not predict mortality \[hazard ratio (HR): 0.984; 95% confidence interval (CI): 0.641 to 1.509; *P* = 0.941\].

![Kaplan--Meier curves showing the survival of those with and without an implantable cardioverter‐defibrillator: (A) patients with non‐ischaemic heart failure and (B) patients with ischaemic heart failure.](EHF2-6-297-g002){#ehf212407-fig-0002}

###### 

Hazard ratio to assess the effect of ICD status on mortality for those with ICM and with NICM based on the matched sample

                         Patients with ICM      Patients with NICM   Interaction *P* value           
  ---------------------- ---------------------- -------------------- ----------------------- ------- -------
  All‐cause death        0.640 (0.448--0.915)   0.015                0.984 (0.641--1.509)    0.941   0.131
  Cardiovascular death   0.713 (0.473--1.075)   0.107                0.967 (0.578--1.618)    0.898   0.365
  Sudden death           0.673 (0.385--1.176)   0.164                0.246 (0.077--0.781)    0.017   0.124

CI, confidence intervals; ICD, implantable cardioverter‐defibrillator; ICM, ischaemic cardiomyopathy; NICM, non‐ischaemic cardiomyopathy.

Of the 669 patients with ICM in the matched cohort, 177 (26.5%) died during follow‐up. These included 43 (19.3%) of the 223 patients with ICDs at baseline and 134 (30.0%) of the 446 matched patients who did not have ICDs. Having an ICD at baseline was significantly associated with lower mortality (HR: 0.640; 95% CI: 0.448 to 0.915; *P* = 0.015). There was a weak evidence of interaction between ICD status and the aetiology of HF (*P* = 0.131).

Secondary outcomes: Cardiovascular and sudden death {#ehf212407-sec-0012}
---------------------------------------------------

Of 279 deaths, a total of 184 (65.9%) were classified as cardiovascular (133 deaths among patients without ICD and 51 deaths among those with ICD). The relation between ICD status and cardiovascular mortality was similar to its relation with all‐cause mortality, though it did not achieve statistical significance in either subgroups (for ICM, HR: 0.713, 95% CI: 0.473 to 1.075, *P* = 0.107; for NICM, HR: 0.967, 95% CI: 0.578 to 1.618; *P* = 0.898; interaction *P* = 0.365).

A total of 97 deaths were classified as sudden (77 deaths among those without ICD and 20 deaths among those with ICD). The association between having ICD and sudden death was not significant among patients with ICM but was significant among patients with NICM (for ICM, HR: 0.673, 95% CI: 0.385 to 1.176, *P* = 0.164; patients with NICM, HR: 0.246, 95% CI: 0.077 to 0.781; *P* = 0.017; interaction *P* = 0.124).

Discussion {#ehf212407-sec-0013}
==========

In this retrospective, propensity‐matched analysis of the WARCEF trial, we found that the presence of ICD at baseline was associated with a lower risk of all‐cause death among those with ICM but not among those with NICM. There was weak evidence of an interaction effect for ICD status and whether a patient had NICM or ICM. These findings are consistent with prior studies showing that the benefit of ICDs is more pronounced in patients with ICM, but ICDs may be less effective in patients with NICM.

Our findings are broadly consistent with the recent literature[6](#ehf212407-bib-0006){ref-type="ref"}, [12](#ehf212407-bib-0012){ref-type="ref"} suggesting that the effect of ICD may be attenuated in patients with NICM. Compared with ICM, NICM is known to be associated with a better left ventricular reverse remodelling,[18](#ehf212407-bib-0018){ref-type="ref"} a better clinical outcome,[19](#ehf212407-bib-0019){ref-type="ref"} and a lower background risk for ventricular arrhythmia.[20](#ehf212407-bib-0020){ref-type="ref"}, [21](#ehf212407-bib-0021){ref-type="ref"} Besides these differences between ICM and NICM, the evidence for the primary prevention of ICD among patients with NICM is less robust.[4](#ehf212407-bib-0004){ref-type="ref"}, [5](#ehf212407-bib-0005){ref-type="ref"}, [6](#ehf212407-bib-0006){ref-type="ref"} The recent DANISH trial, which randomized 1116 patients with NICM to receive conventional therapy or an ICD, demonstrated no significant association between the presence of ICD and all‐cause mortality among NICM patients (HR: 0.87; 95% CI: 0.68 to 1.12; *P* = 0.28). Similarly to the WARCEF population, the rates of optimal medical therapy in DANISH trial participants were high. Studies have consistently shown that the optimal medical therapies, such as ACE‐Inhibitors,[22](#ehf212407-bib-0022){ref-type="ref"} ARBs,[23](#ehf212407-bib-0023){ref-type="ref"} beta‐blockers,[24](#ehf212407-bib-0024){ref-type="ref"} mineralocorticoid‐receptor antagonists,[25](#ehf212407-bib-0025){ref-type="ref"} or combinations of these medications,[26](#ehf212407-bib-0026){ref-type="ref"} all reduce the rate of cardiovascular death or sudden death. It is, therefore, possible that sudden death in medically optimized HF patients may be less common, leading to diminished benefit from ICDs.

It may be surprising that in our analysis, ICD status predicted mortality in patients with ICM, but its association on sudden death was not found to be statistically significant. Conversely, ICD status did not predict mortality in patients with NICM in our analysis but did have a strong association with sudden death. However, these results regarding sudden death must be interpreted with caution, as the adjudication in WARCEF was not blinded to defibrillator status, and the number of sudden death events was small. In addition, the DANISH trial[6](#ehf212407-bib-0006){ref-type="ref"} has shown that in the populations with NICM in which ICDs did not reduce overall mortality, ICDs may nonetheless have an apparent effect on sudden death (HR: 0.50; 95% CI: 0.31 to 0.82; *P* = 0.005).

Despite our findings, there remains uncertainty regarding the current recommendation for ICD implantation in patients with NICM. Subsequent analysis of the DANISH trial has shown that ICD implantation may be beneficial in NICM patients younger than 70 years of age.[27](#ehf212407-bib-0027){ref-type="ref"} Compared with the DANISH trial in which the median age was 63 years old, NICM patients in the WARCEF trial were considerably younger, with a median age of 58 years old. It is therefore unclear if age or other clinical risk predictors might be helpful in guiding decision for ICD implantation in patients with NICM. Furthermore, statistical power remains a concern for both the DANISH trial and our analysis, as recent meta‐analyses continue to suggest a survival benefit for ICD implantation among patients with NICM[7](#ehf212407-bib-0007){ref-type="ref"}, [8](#ehf212407-bib-0008){ref-type="ref"}, [9](#ehf212407-bib-0009){ref-type="ref"}, [10](#ehf212407-bib-0010){ref-type="ref"}, [11](#ehf212407-bib-0011){ref-type="ref"} even after the inclusion of the DANISH trial. Nonetheless, differences in patient clinical characteristics and contemporary background medical therapy may affect the validity of these findings, and thereby, future studies with carefully defined patient selection criteria will be needed to clarify whether ICD implantation can be beneficial in subgroups of patients with NICM.[28](#ehf212407-bib-0028){ref-type="ref"}

Limitations {#ehf212407-sec-0014}
-----------

First, our study was retrospective and therefore necessarily hypothesis generating. ICD status was not randomly assigned, which raised the potential for indication bias. To address this, we used a propensity‐matching approach, which can address confounding from known baseline covariates. However, residual confounding may still be present, because the decision to place an ICD is often nuanced and incorporates additional unmeasured patient clinical and psychosocial characteristics. Second, past medical history of cardiac arrest was not recorded at baseline, and it is possible that a small number of patients received ICDs for secondary prevention. However, these patients are more likely to benefit from ICDs,[29](#ehf212407-bib-0029){ref-type="ref"} which therefore would not affect our null finding for patients with NICM. Third, we did not collect detailed information on CRT status at baseline, or whether patients received ICD and/or CRT during follow‐up. We also did not collect electrocardiogram data such as QRS duration or presence of left bundle branch block. We therefore were not able to control for these potential confounders. Fourth, WARCEF was limited to patients in sinus rhythm at baseline, which may limit the external validity of our analysis. Fifth, our propensity matching led to exclusion of more than half of the patients with NICM from the current analysis, and our findings therefore must be interpreted cautiously.

Conclusions {#ehf212407-sec-0015}
-----------

In this propensity‐matched, retrospective analysis of data from the WARCEF trial, we found that the presence of ICD at baseline conveyed a survival benefit in those with ICM but not in those with NICM. Our results are consistent with previous literature demonstrating that ICDs are beneficial in patients with ICM and corroborated the results of the DANISH trial, which suggested that beneficial effects of ICDs are attenuated in patients with NICM.
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